Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

panpharma - benzylpenicillinnatrium - pulver til injektions-/infusionsvæske, opløsning - 6 g

Den Europæiske Union - dansk - EMA (European Medicines Agency)

les laboratoires servier - irinotecan anhydrous free-base - bukspyttkjertel-neoplasmer - antineoplastiske midler - behandling af metastatisk adenokarcinom i pancreas, i kombination med 5 fluorouracil (5 fu) og leucovorin (lv), hos voksne patienter, der har udviklet sig efter gemcitabin baseret terapi.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

gilead sciences ireland uc - idelalisib - lymphoma, non-hodgkin; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, other antineoplastic agents - zydelig is indicated in combination with an anti‑cd20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (cll):who have received at least one prior therapy, oras first line treatment in the presence of 17p deletion or tp53 mutation in patients who are not eligible for any other therapies. zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (fl) that is refractory to two prior lines of treatment.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

secura bio limited - duvelisib - leukemia, lymphocytic, chronic, b-cell; lymphoma, follicular - antineoplastiske midler - copiktra monotherapy is indicated for the treatment of adult patients with: relapsed or refractory chronic lymphocytic leukaemia (cll) after at least two prior therapies.  follicular lymphoma (fl) that is refractory to at least two prior  systemic therapies.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

newbury pharmaceuticals ab - lapatinibditosylatmonohydrat - filmovertrukne tabletter - 250 mg

Den Europæiske Union - dansk - EMA (European Medicines Agency)

roche registration gmbh - cobimetinibhemifumarat - melanom - antineoplastiske midler - cotellic er indiceret til brug i kombination med vemurafenib til behandling af voksne patienter med uopløseligt eller metastatisk melanom med en braf v600 mutation.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

novartis europharm limited - secukinumab - arthritis, psoriatic; psoriasis; spondylitis, ankylosing - immunosuppressiva - plaque psoriasiscosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy. hidradenitis suppurativa (hs)cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic hs therapy. psoriasis arthritiscosentyx, alene eller i kombination med methotrexat (mtx), er indiceret til behandling af aktiv psoriasis artrit hos voksne patienter, når svar på tidligere sygdomsmodificerende anti-reumatiske lægemidler (dmard) behandling har været mangelfuld. aksial spondyloarthritis (axspa)ankyloserende spondylitis (som, røntgen aksial spondyloarthritis)cosentyx er indiceret til behandling af aktiv ankyloserende spondylitis i voksne, der har reageret tilstrækkeligt til konventionel behandling. non-radiographic axial spondyloarthritis (nr-axspa)cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (nsaids). juvenile idiopathic arthritis (jia)enthesitis-related arthritis (era)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. juvenile psoriatic arthritis (jpsa)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

gilead sciences international ltd - elvitegravir - hiv infektioner - antivirale midler til systemisk anvendelse - vitekta co administreres med en ritonavir-boostet protease hæmmer og med andre antiretrovirale stoffer, er indiceret til behandling af human immundefekt virus 1 (hiv-1) infektion hos voksne, der er smittet med hiv-1 uden kendte mutationer forbundet med modstand mod elvitegravir.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

vitabalans oy - loperamidhydrochlorid - filmovertrukne tabletter - 2 mg

Den Europæiske Union - dansk - EMA (European Medicines Agency)

instituto grifols s.a. - fostamatinib dinatrium - trombocytopeni - andre systemiske hemostatics - tavlesse er indiceret til behandling af kronisk immun trombocytopeni (itp) hos voksne patienter, der er refraktære over for andre behandlinger.